CN106540036A - A kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage - Google Patents

A kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage Download PDF

Info

Publication number
CN106540036A
CN106540036A CN201510605930.4A CN201510605930A CN106540036A CN 106540036 A CN106540036 A CN 106540036A CN 201510605930 A CN201510605930 A CN 201510605930A CN 106540036 A CN106540036 A CN 106540036A
Authority
CN
China
Prior art keywords
kaixin
capsule
myocardial damage
cardiac arrest
dog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510605930.4A
Other languages
Chinese (zh)
Inventor
白建学
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510605930.4A priority Critical patent/CN106540036A/en
Publication of CN106540036A publication Critical patent/CN106540036A/en
Pending legal-status Critical Current

Links

Abstract

A kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage, healthy experimental dog are divided into Kaixin Capsule group;Replicate sudden cardiac arrest and recovery model.

Description

A kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage
Technical field
The present invention relates to a kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage, the method that specifically a kind of Kaixin Capsule is treated to dog cardiac arrest myocardial damage.
Background technology
Currently known cardiac troponin (cTnT) is a kind of structural protein, it is present in My, there is the subunit of 3 kinds of different structures, TnT (cTnT), Troponin I (cTnI), TnC (cTnC), by coded by different genes.Wherein cTnT is the specific antigen of heart, is existed to dissociate and combine two kinds of forms, rich content in cardiac muscle.Just blood is released into rapidly when myocardial damage, the half-life is 120min in blood, and its release dynamics feature is time of occurrence morning in blood, and the persistent period is long, and peak concentration is high.Used as the mark of myocardial damage, its species specificity is very strong, and cross reaction hardly occurs with skeletal troponin.CTnT is considered as that current reflecting myocardium damages one of best direct pathology blood serum designated object because of its height Cardiac-specific, high sensitive, the early stage property of diagnosis, and its diagnostic value is considerably beyond conventional creatine phosphate isozyme (CKMB) containing M and B subunits etc..Therefore, determining serum cTnT concentration can the impaired order of severity of reflecting myocardium.There is the myocardial damage of higher proportion in critical illness early stage, it is believed that myocardial damage is relevant with recovery patient's high mortality.After cardiac arrest, Success rate is relatively low, and the research of the past shows that myocardial damage is the one of the main reasons for causing patient's Deaths after success of cardiopulmonary resuscitation.
The content of the invention
Diagnostic criteria:
1. materials and methods:Experimental apparatus;5F SwanGanz float catheters (ARROW companies of the U.S., lot number:AT07065);PM9000 multiparameter hemodynamic monitoring instrument (Shenzhen Mai Rui medical device corporations);Physiological record system (BIOPAC companies of the U.S.) is led BIOPAC MP150 more;4222 endocardiac defibrillation devices of Power Unit (SanEi companies of the U.S.);Self-control low-voltage AC electric shock cause is quivered device;TKR300CG computer jet oxygenrespirators (Jiangxi Te Li anesthesia respirations equipment company);80 average adult's tracheal intubatioies of ID;Columba livia board TGI16GA low-temperature and high-speed centrifuges (Anting Scientific Instrument Factory, Shanghai);Leica300Q Win Colour Pathologic image analysis instrument (Germany).A. experimental technique;From healthy experimental dog 15, male and female do not limit (13~15kg), are provided by Traditional Chinese Medicine University Of Guangzhou's Experimental Animal Center, are randomly divided into 3 groups, 5 per group.Sham operated rats:Only row opens breast sham-operation process;Model group:Open after breast causes to quiver and routinely recover;Kaixin Capsule group:Add normal saline to be made into 500g/L concentration with Kaixin Capsule before experiment, mixing is slightly heated into scattered paste shape, admixes in dog same day feedstuff, for experiment after continuous nursing 5d, open after breast causes to quiver and routinely recover, after recovery, do not use any vaso-active substance.Every dog is pressed into 1mL kg-1 intraperitoneal injection of anesthesia with 30g/L pentobarbital sodiums, tracheal intubation continues rower II lead electrocardiogram monitor of standard and blood oxygen saturation monitoring;Float catheter is inserted from right external jugular vein, and multiparameter hemodynamic monitoring instrument and physiological record system is led more and is connected, by the change of observation pressure and waveform, conduit is sent into into pulmonary artery;Right carotid intubation with lead physiological record system more and be connected, continuously measure mean arterial pressure (MAP);5th intercostal opens breast on the left of the breastbone, when maying be seen indistinctly to pleura, that is, connects oxygenrespirator row high frequency and penetrates oxygen ventilation, expose heart.Model group and Chinese medicine group dog are quivered with low-voltage AC (3V, 25mA, 01s) induction room, stop mechanical ventilation simultaneously, after continuing 4min, recover mechanical ventilation, row heart compression, defibrillation first is carried out with 5w/s unidirectional currents after 30s, defibrillation is repeated with 10w/s if unsuccessful, until spontaneous circulation is set up.B. collection of specimens and process;After spontaneous circulation is recovered, 5min, 30min, 90min, 180min take central vein blood 2mL by internal jugular vein intubation respectively, injection is without in anticoagulant test tube, after standing 20min, the supernatant for separating out is transferred in 3mL centrifuge tubes with cover, plus after balance pipe, enter 4 DEG C of refrigerated centrifuge, 3000r/min centrifugation 20min, take serum and -20 DEG C of preservations are put with TnT to be measured (cTnT) content;Before measure, specimen is melted again, take serum 01mL measure.The sacrificed by exsanguination animal after spontaneous circulation 180min is recovered, wins rapidly heart, and myocardial slices are fixed with formalin and glutaraldehyde respectively by the nearly apex of the heart position cardiac muscular tissue of clip left ventricle.CTnT and Cardiac muscle sections detection;CTnT test kits are provided by Beijing North Institute of Biological Technology, and by specification is detected.Optics pathology adopts NagarOlsen stainings;Dyeed, checked by Traditional Chinese Medicine University Of Guangzhou's Pathological Staff Room, Ultrastructural pathology is carried out by Traditional Chinese Medicine University Of Guangzhou's Electron Microscopy Room.Graphical analyses;Using Pathologic image analysis instrument, use morphometry method, to measuring under each group myocardial slices visual field, calculate myocardium basic fuchsin stained positive area (μm 2) total value for meeting color separation thresholding condition, with the part of non-white background on the same visual field, the i.e. ratio of visual field cardiac muscle gross area value (μm 2).Ratio is bigger, illustrates that pathological changes myocardial cell content is more, statistical procedures;Data represent that with (± s) each group of data carries out homogeneity test of variance, and test of homogeneity level P > 005 is that variance is neat, and variance analyses are carried out after homogeneous.Between group, the same period compares two-by-two using one factor analysis of variance (Oneway ANOVA).2. result;Impact of the Kaixin Capsule to serum cTnT contents;Model group serum cTnT is raised after spontaneous circulation recovery immediately, and As time goes on, cTnT concentration also increases successively, and day part cTnT concentration is compared with sham operated rats significant difference (P < 005);After recovery, 90min, 180min Kaixin Capsule group cTnT concentration value is below model group (P < 005).Each group myocardial histopathology inspection result;The substantially no qualified stained positive point of sham operated rats;The model group stained positive point gross area accounts for the 6992% of whole myocardial area ratio, compares with Kaixin Capsule group with significant difference (P < 005).The visible peach pathological changes cardiac muscle fiber of myocardial slices of Kaixin Capsule group, but density ratio model group is little.Electronic Speculum result shows that the myocardium myofilament dissolving of model group is even ruptured, and arranges in disorder, the normal Z heading line offs under multiple visuals field;Mitochondrion height swelling, its internal normal ridge arrangement completely lose;T pipes, myoplasm net height swelling;Glycogen granule is reduced, and it is damaged that dissolving occurs in cell membrane.Although cellularity damage also occurs in Kaixin Capsule group, degree of injury is light compared with model group.
Goal of the invention:After cardiac arrest, Success rate is relatively low, and the research of the past shows that myocardial damage is the one of the main reasons for causing patient's Deaths after success of cardiopulmonary resuscitation.Chinese medicine Kaixin Capsule secondary early stage heart failure of Ventricular Remodeling, ischemic heart desease etc. after myocardial ischemia, heart infarction is clinical and zoopery in achieved with good myocardial damage effect, and there is no the report that application in TCM is prevented and treated after recovery myocardial damage both at home and abroad.Therefore, herein on dog cardiac arrest recovery model, inquire into whether the medicine has preventive and therapeutic effect to the myocardial damage after the recovery of dog cardiac arrest.After this result of study also demonstrate that recovery, cTnT can be raised immediately, elapse over time, and concentration also increases successively, point out the early stage after recovery to may occur in which myocardial damage.
Technical scheme:Method health experimental dog 15, is randomly divided into sham operated rats, model group, Kaixin Capsule group;Sudden cardiac arrest and recovery model are replicated, 5min, 30min, 90min, 180min take central vein blood by internal jugular vein intubation after spontaneous circulation is recovered respectively, observe the changes of contents of day part TnT (cTnT);Cardiac muscle sections are in light microscopic and the structure change of electric Microscopic observation myocardial damage.
Invention beneficial effect:Model group dog serum cTnT is raised after spontaneous circulation recovery immediately, and day part cTnT concentration is compared with sham operated rats significant difference (P < 005);Kaixin Capsule group 90min and 180min period cTnT concentration values after recovery are below model group (P < 005).The cardiac muscle stained positive point gross area increase of light microscopic drag group, comparing with sham operated rats has significant difference (P < 005);The Kaixin Capsule group positive gross area is reduced, and comparing with model group has significant difference (P < 005);Under Electronic Speculum, although Kaixin Capsule group there is cellularity damage, but degree of injury is light compared with model group.Kaixin Capsule on Myocardial Injury in Dogs After Resuscitation of Cardiac Arrest has good preventive and therapeutic effect.
Preferred forms:Carry out Drug therapy.
Innovation:This new patent of invention is related to a kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage, and the mechanism that Kaixin Capsule mitigates myocardial damage may have several respects:(1) in resuscitation process; because protective effect of the Chinese medicine to cardiac muscle makes Epinephrine dose application less; defibrillation number of times is reduced, therefore the myocardial damage caused by the medicine and mechanical factor by when recovery is also less, this possibly recover after 5min model group cTnT concentration the reason for be higher than Chinese medicine group;(2), after Successful Resuscitation, the plurality of Chinese effective ingredient in blood continues to play a role, and protects myocardial ultramicrostructure;(3) after recovering, the hemodynamics of Chinese medicine group are relatively stable (particular content will be delivered in a separate paper), prevent to some extent the reperfusion injury of myocardial cell.It is therefore believed that Kaixin Capsule has good preventive and therapeutic effect to myocardial damage after cardiac arrest recovery.

Claims (1)

1. a kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage, healthy experimental dog are divided into Kaixin Capsule group;Sudden cardiac arrest and recovery model are replicated, 5min, 30min, 90min, 180min take central vein blood by internal jugular vein intubation after spontaneous circulation is recovered respectively, observe the changes of contents of day part TnT (cTnT);Cardiac muscle sections are in light microscopic and the structure change of electric Microscopic observation myocardial damage.
CN201510605930.4A 2015-09-22 2015-09-22 A kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage Pending CN106540036A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510605930.4A CN106540036A (en) 2015-09-22 2015-09-22 A kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510605930.4A CN106540036A (en) 2015-09-22 2015-09-22 A kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage

Publications (1)

Publication Number Publication Date
CN106540036A true CN106540036A (en) 2017-03-29

Family

ID=58364606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510605930.4A Pending CN106540036A (en) 2015-09-22 2015-09-22 A kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage

Country Status (1)

Country Link
CN (1) CN106540036A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109106361A (en) * 2017-06-23 2019-01-01 周厚荣 A kind of monitoring device inducing animal ventricular fibrillation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109106361A (en) * 2017-06-23 2019-01-01 周厚荣 A kind of monitoring device inducing animal ventricular fibrillation

Similar Documents

Publication Publication Date Title
Chen et al. Subcutaneous administration of brain natriuretic peptide in experimental heart failure
Lin et al. Model of cardiac arrest in rats by transcutaneous electrical epicardium stimulation
Dietz Control of atrial natriuretic factor release from a rat heart-lung preparation
Neumar et al. Estimation of myocardial ischemic injury during ventricular fibrillation with total circulatory arrest using high-energy phosphates and lactate as metabolic markers
Brookes Arteriolar blockade: a method of measuring blood flow rates in the skeleton.
DeLuca et al. Metabolism of tritiated vitamin D3 in familial vitamin D-resistant rickets with hypophosphatemia
CN113456621B (en) Application of curcumin metabolite in preparation of medicine for treating myocardial ischemia-related injury
CN106540036A (en) A kind of method that Kaixin Capsule is treated to dog cardiac arrest myocardial damage
CN103385995B (en) Traditional Chinese medicine compound for treating arrhythmia and preparation method thereof
CN115089622B (en) Celery exosome composition and preparation method and application thereof
Macauley Physical therapy management of two patients with stage D heart failure in the cardiac medical intensive care unit
Bing et al. Physiology of the myocardium
CN107789475A (en) A kind of Kaixin Capsule is to the protective effect after cardiac arrest recovery
CN113730388A (en) Application of sodium caprylate in preparation of medicine for improving cardio-pulmonary resuscitation effect and multi-organ dysfunction after cardio-pulmonary resuscitation
Fu et al. Increased histamine and 5-HT in portal vein plasma and mesenteric lymph during brief ischemia and reperfusion
Guo et al. Polyethylene glycol-20k reduces post-resuscitation cerebral dysfunction in a rat model of cardiac arrest and resuscitation: A potential mechanism
CN108210487A (en) Application of the Sodium Houttuyfonate in treatment heart failure and/or antiarrhythmic medicament is prepared
CN114010658B (en) TREM2 hi Application of macrophage in preparing medicine for treating cardiac dysfunction
CN104814954B (en) A kind of pharmaceutical preparation and the application in treatment myocardial ischemia and gastritis medicine is prepared
Gaucher et al. A double blind randomized placebo controlled study of cholera treatment with highly diluted and succussed solutions
CN108904714A (en) A kind of preparation method of Chinese medicine that treating cardiovascular disease
CN108379555A (en) Applications of the FGF21 in the drug for preparing hypertension and/or angiosis damage that treatment is caused by angiotensinⅡ
CN107648211A (en) Application of the gallic acid in angiocardiopathy is prevented and treated
Szabo et al. Ivabradine acutely improves cardiac Ca handling and function in a rat model of Duchenne muscular dystrophy
Crawford et al. 19 Testing causality in the association of plasma cortisol with risk of coronary heart disease: a mendelian randomisation study

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170329